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Inhibitory effect of clofazimine on CYP-selective probe substrate metabolism
The potential of clofazimine to inhibit human cytochrome P450 (CYP) enzyme activity was assessed in pooled human liver microsomes (HLM) by testing the effect of increasing concentrations of clofazimine on the in vitro metabolism of several probe substrates whose metabolism is known to be selective for individual CYP enzymes. CYP activity was assessed using the probe reactions phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), amodiaquine N-deethylation (CYP2C8), diclofenac 4′-hydroxylation (CYP2C9), S-mephenytoin 4′-hydroxylation (CYP2C19), bufuralol 1′-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and midazolam-1′-hydroxylation or testosterone 6β-hydroxylation (CYP3A). Probe substrate concentrations used for these determinations were less than or equal to their reported Michaelis-Menten constant (K m ) values. For reversible inhibition, the incubations (37°C, 10-20 min) were composed of (final concentrations) potassium phosphate buffer (100 mM, pH 7.4), nicotinamide adenine dinucleotide phosphate (NADPH) (1 mM), magnesium chloride (5 mM), HLM protein (0.05-0.5 mg protein/mL), probe substrate (1 μM midazolam or coumarin, 5 μM phenacetin, diclofenac, or bufuralol, 2 μM amodiaquine, 10 μM chlorzoxazone, 15 μM S-mephenytoin, 25 μM bupropion, or 50 μM testosterone), and varying concentrations of clofazimine (0-10 μM). After preincubation for 3 min, the reactions were initiated by addition of NADPH and terminated by addition of acetonitrile (2 volumes). These were conducted in a 96-well plate format at 37°C using a TECAN Freedom Evo system (Zurich, Switzerland). The reactions were initiated by adding NADPH after at least a 3-min thermal equilibrium. Incubations were terminated by the addition of acetonitrile (200 μL). Due to the poor aqueous solubility of clofazimine in HLM incubation mixture, the organic content was increased to ~5% for all the experiments. Formation of probe substrate metabolites from the above samples, acetaminophen, 7-hydroxycoumarin, hydroxybupropion, N-desethylamodiaquine, 4′-hydroxydiclofenac, 4′-hydroxy-S-mephenytoin, 1′-hydroxybufuralol, 6-hydroxychlorzoxazone, 1′-hydroxymidazolam, and 6β-hydroxytestosterone was determined by liquid chromatography-tandem mass spectrometry (LC- 
Mixed inhibition (partial):
where, v is initial rate of metabolism, V max is maximal rate of metabolism, K m is Michaelis-
To investigate the possibility of time-dependent inhibition (TDI) of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5, clofazimine (0-10 µM) was preincubated with HLM, using protein concentrations of 1.0 mg microsomal protein/mL for CYP1A2, CYP2B6, and CYP2C19 and 0.5 mg microsomal protein/mL for CYP2C8, CYP2C9, CYP2D6, and CYP3A4/5. The concentrations of clofazimine were 0.1, 0.5, 1, 2.5, 5, and 10 µM for all experiments. The assessment of the TDI of the total seven CYP enzymes was divided into two experiments. The first experiment included CYP2B6, CYP2C8, CYP2D6, and CYP3A4/5, while the second experiment included CYP1A2, CYP2C9, and CYP2C19. After specified incubation times, aliquots (5 µL) of the pre-incubation mixture were transferred to a 95 µL enzyme activity assay mixture to determine the CYP activity remaining. The concentrations of probe substrates in the enzyme activity assay were 50 μM phenacetin (CYP1A2), 1.5 mM bupropion (CYP2B6), 20 μM amodiaquine (CYP2C8), 25 μM diclofenac (CYP2C9), 300 μM Smephenytoin (CYP2C19), 25 μM bufuralol (CYP2D6), and 20 μM midazolam (CYP3A4/5). The enzyme activity assay reactions were incubated at 37°C for 6 min and terminated as above.
Positive-control time-dependent inhibitors included furafylline (CYP1A2), ticlopidine (CYP2B6 and CYP2C19), gemfibrozil glucuronide (CYP2C8), tienilic acid (CYP2C9), paroxetine (CYP2D6), and troleandomycin (CYP3A4). Sample preparation for analysis of probe substrate metabolite formation by LC-MS/MS was as described above. For positive controls, the inactivation parameters k inact (maximum inactivation rate) and K I (concentration at ½ kinact) were determined by plotting the natural log of the percentage of control activity remaining following incubations with increasing inhibitor concentration against time of pre-incubation. The absolute value of the observed rate of inactivation (k obs ) was then plotted against inhibitor concentration ([I] ) and the data analyzed by non-linear regression using the equation:
Unbound fraction of clofazimine in microsomes (fumic)
Clofazimine (1 or 10 µM) was mixed with pooled HLM at various protein concentrations (0.025, 0.05, or 0.5 mg protein/mL) in 100 mM potassium phosphate buffer (pH 7.4) containing 5 mM MgCl 2 (final concentrations) using glass vials. Aliquots of 0.5 mL of each sample were transferred to ultracentrifuge tubes and incubated for 10 min at 37°C in an Eppendorf Thermomixer (Eppendorf, Germany). The samples were centrifuged at 306,000 × g for 30 min at ~37°C in a Sorvall ® RC-M120GX Micro-ultracentrifuge (Newtown, CT, US). The ultracentrifuge was allowed to stop without using the brake. Two aliquots from the resulting supernatants were removed from individual tubes for LC-MS/MS analysis and protein analysis, respectively. Prior to ultracentrifugation, 50 µL aliquots of the samples were removed from each ultracentrifuge tube for LC-MS/MS analysis. The MS area ratio (peak area of clofazimine/peak area of clofazimined7) of the pre-and post-ultracentrifugation samples obtained from LC-MS/MS analysis was used for the calculation of unbound fraction (fu mic ) with the following equation:
where, Area ratio total is the area ratio of the sample before ultracentrifugation and Area ratio free is the area ratio in the supernatant after ultracentrifugation. µM, micromole; B/P, blood-to-plasma ratio; CL R , renal clearance; CV, coefficient of variation; f a , fraction of dose absorbed; fu gut , unbound fraction of drug in enterocyte; fu mic , fraction unbound in the microsomes; fu p , fraction unbound in the plasma; g, gram; h, hour; HLM, human liver microsomes; k a , absorption rate constant; K m,u , unbound Michaelis-Menten constant; LogP, log of the partition coefficient; mol, moles; pmol, picomole; PBPK, physiologically based pharmacokinetic P eff.man , effective permeability in man; pKa, acid dissociation constant; Q gut , nominal flow in gut model; V max , maximum velocity; V ss , volume of distribution at steady state
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